Complete Remission in a Patient with Human Herpes Virus-8 Negative Multicentric Castleman Disease Using CHOP Chemotherapy
Hee Yeon Seo, Eui Bae Kim, Jee Won Kim, Bong Kyoung Shin, Seok Jin Kim, Byung Soo Kim
Cancer Res Treat. 2009;41(2):104-107.   Published online 2009 Jun 30     DOI: https://doi.org/10.4143/crt.2009.41.2.104
Citations to this article as recorded by Crossref logo
Autoreactive Antibodies Associated with Castleman Disease Triad
Jacqueline A. Turner, Ali Hakimi, Hannah Lee, Jeffrey T. Schowinsky, Jeffrey M. Sippel, Bradford J. Siegele, Raul M. Torres, William A. Robinson, Necil Kütükçüler
Case Reports in Immunology.2024; 2024: 1.     CrossRef
Clinicopathological Profile of Castleman’s Disease in Indian Population: Experience From a Tertiary Care Center
Ashok Singh, Suvendu Purkait, Saumyaranjan Mallick, Prashant Ramteke, Chandan Krushna Das, Ajay Gogia, Maher Chand Sharma, Lalit Kumar
Indian Journal of Hematology and Blood Transfusion.2020; 36(2): 254.     CrossRef
Analysis of clinical characteristics and prognosis factors of 71 cases with HIV-negative Castleman’s disease: hypoproteinemia is an unfavorable prognostic factor which should be treated appropriately
Xuan Lan, Zhaoming Li, Mingzhi Zhang
Journal of Cancer Research and Clinical Oncology.2018; 144(7): 1265.     CrossRef
Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease
Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young
Blood.2017; 129(12): 1658.     CrossRef
Clinical management of HIV-associated hematologic malignancies
Chia-Ching J. Wang, Lawrence D. Kaplan
Expert Review of Hematology.2016; 9(4): 361.     CrossRef
Practical Management of Castleman's Disease
Musa Fares Alzahrani, Mansoor Radwi, Heather A. Leitch
Acta Haematologica.2016; 136(1): 16.     CrossRef
Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome
Musa Alzahrani, Mark C. Hull, Christopher Sherlock, Deborah Griswold, Chantal S. Leger, Heather A. Leitch
Leukemia & Lymphoma.2015; 56(5): 1246.     CrossRef
An unusual presentation: A case of Multicentric Castleman's disease presenting as bilateral pleural effusions
Priya K. Simoes, Narender Annapureddy, Vaidehi Avadhani, Gangajal Kasnia, Girish N. Nadkarni
HIV & AIDS Review.2015; 14(3): 84.     CrossRef
Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance
Lucie M. Turcotte, Colleen K. Correll, Robyn C. Reed, Christopher L. Moertel
Pediatric Blood & Cancer.2014; 61(4): 737.     CrossRef
Diagnosis and Management of Castleman Disease
Jacob D. Soumerai, Aliyah R. Sohani, Jeremy S. Abramson
Cancer Control.2014; 21(4): 266.     CrossRef
Multicentric Castleman’s Disease: A Challenging Diagnosis
Györgyi Műzes, Ferenc Sipos, Judit Csomor, Lídia Sréter
Pathology & Oncology Research.2013; 19(3): 345.     CrossRef
Clinical Features and Outcomes of Head and Neck Castleman Disease
Yan-Feng Chen, Wei-Dong Zhang, Chuan-Zheng Sun, Dian OuYang, Wen-Kuan Chen, Rong-Zhen Luo, Ming-Wei Wu
Journal of Oral and Maxillofacial Surgery.2012; 70(10): 2466.     CrossRef
Castleman's Disease: From Basic Mechanisms to Molecular Therapeutics
Hazem E. El-Osta, Razelle Kurzrock
The Oncologist.2011; 16(4): 497.     CrossRef